QQQ   386.32 (-0.93%)
AAPL   189.43 (-0.95%)
MSFT   369.14 (-1.43%)
META   320.02 (-1.48%)
GOOGL   129.27 (-1.96%)
AMZN   144.84 (-1.49%)
TSLA   235.58 (-1.36%)
NVDA   455.10 (-2.68%)
NIO   7.32 (+2.38%)
BABA   73.03 (-1.30%)
AMD   118.57 (-2.32%)
T   16.67 (-0.60%)
F   10.70 (+1.13%)
MU   74.29 (-2.16%)
CGC   0.76 (+22.72%)
GE   121.50 (-0.82%)
DIS   92.01 (-0.62%)
AMC   7.50 (+9.18%)
PFE   29.25 (+1.18%)
PYPL   59.85 (+0.34%)
XOM   102.43 (-0.54%)
QQQ   386.32 (-0.93%)
AAPL   189.43 (-0.95%)
MSFT   369.14 (-1.43%)
META   320.02 (-1.48%)
GOOGL   129.27 (-1.96%)
AMZN   144.84 (-1.49%)
TSLA   235.58 (-1.36%)
NVDA   455.10 (-2.68%)
NIO   7.32 (+2.38%)
BABA   73.03 (-1.30%)
AMD   118.57 (-2.32%)
T   16.67 (-0.60%)
F   10.70 (+1.13%)
MU   74.29 (-2.16%)
CGC   0.76 (+22.72%)
GE   121.50 (-0.82%)
DIS   92.01 (-0.62%)
AMC   7.50 (+9.18%)
PFE   29.25 (+1.18%)
PYPL   59.85 (+0.34%)
XOM   102.43 (-0.54%)
QQQ   386.32 (-0.93%)
AAPL   189.43 (-0.95%)
MSFT   369.14 (-1.43%)
META   320.02 (-1.48%)
GOOGL   129.27 (-1.96%)
AMZN   144.84 (-1.49%)
TSLA   235.58 (-1.36%)
NVDA   455.10 (-2.68%)
NIO   7.32 (+2.38%)
BABA   73.03 (-1.30%)
AMD   118.57 (-2.32%)
T   16.67 (-0.60%)
F   10.70 (+1.13%)
MU   74.29 (-2.16%)
CGC   0.76 (+22.72%)
GE   121.50 (-0.82%)
DIS   92.01 (-0.62%)
AMC   7.50 (+9.18%)
PFE   29.25 (+1.18%)
PYPL   59.85 (+0.34%)
XOM   102.43 (-0.54%)
QQQ   386.32 (-0.93%)
AAPL   189.43 (-0.95%)
MSFT   369.14 (-1.43%)
META   320.02 (-1.48%)
GOOGL   129.27 (-1.96%)
AMZN   144.84 (-1.49%)
TSLA   235.58 (-1.36%)
NVDA   455.10 (-2.68%)
NIO   7.32 (+2.38%)
BABA   73.03 (-1.30%)
AMD   118.57 (-2.32%)
T   16.67 (-0.60%)
F   10.70 (+1.13%)
MU   74.29 (-2.16%)
CGC   0.76 (+22.72%)
GE   121.50 (-0.82%)
DIS   92.01 (-0.62%)
AMC   7.50 (+9.18%)
PFE   29.25 (+1.18%)
PYPL   59.85 (+0.34%)
XOM   102.43 (-0.54%)

Accolade Stock Price, News & Analysis (NASDAQ:ACCD)

$9.14
+0.08 (+0.88%)
(As of 12/4/2023 ET)
Compare
Today's Range
$8.81
$9.20
50-Day Range
$6.50
$10.76
52-Week Range
$6.33
$17.00
Volume
616,806 shs
Average Volume
628,072 shs
Market Capitalization
$696.76 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.14

Accolade MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.69 Rating Score
Upside/​Downside
65.7% Upside
$15.14 Price Target
Short Interest
Healthy
4.11% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.89
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$74,397 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.56) to ($1.38) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.67 out of 5 stars

Business Services Sector

37th out of 301 stocks

Business Services, Not Elsewhere Classified Industry

12th out of 85 stocks


ACCD stock logo

About Accolade Stock (NASDAQ:ACCD)

Accolade, Inc., together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and virtual primary care physicians. It also provides medical opinion and decision support services; and technology and administrative services to the medical practice PCs providing virtual primary care services. The company serves employers who provide their employees and their employees' families a single place to turn for their health, healthcare, and benefits needs. Accolade, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.

ACCD Stock Price History

ACCD Stock News Headlines

Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
Expert Ratings for Accolade
Accolade Inc Ordinary Shares ACCD
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
Why Shares of Accolade Fell This Week
Accolade (ACCD) Gets a Buy from D.A. Davidson
Accolade Announces Results for Fiscal Second Quarter 2024
Why Accolade Stock Is Falling After-Hours
See More Headlines
Receive ACCD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Accolade and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
10/04/2023
Today
12/04/2023
Next Earnings (Estimated)
1/08/2024
Fiscal Year End
2/29/2024

Industry, Sector and Symbol

Industry
Business services, not elsewhere classified
Sub-Industry
N/A
Current Symbol
NASDAQ:ACCD
Fax
N/A
Employees
2,370
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$15.14
High Stock Price Target
$19.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+65.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.69
Research Coverage
13 Analysts

Profitability

Net Income
$-459,650,000.00
Pretax Margin
-37.19%

Debt

Sales & Book Value

Annual Sales
$380.06 million
Book Value
$6.51 per share

Miscellaneous

Free Float
69,905,000
Market Cap
$696.76 million
Optionable
Not Optionable
Beta
2.06
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Mr. Rajeev Singh (Age 55)
    Chairman of the Board & CEO
    Comp: $778.5k
  • Mr. Robert Cavanaugh (Age 54)
    President
    Comp: $582.63k
  • Mr. Stephen H. Barnes CPA (Age 51)
    CFO & Treasurer
    Comp: $557.5k
  • Ms. Kristen Bruzek
    Senior Vice President of Operations
  • Mr. Colin McHugh (Age 44)
    Chief Accounting Officer
  • Mr. Todd Friedman
    Senior Vice President of Investor Relations
  • Mr. Richard Eskew (Age 48)
    Executive VP, General Counsel, CCO & Secretary
  • Ms. Jennifer Hanson
    Executive VP & Chief Human Resource Officer
  • Mr. Drew Garner
    Executive Vice President of Engineering
  • Dr. Shantanu Nundy M.B.A.
    M.D., Executive VP of Care Delivery, Chief Health Officer & Member of the Medical Advisory Board














ACCD Stock Analysis - Frequently Asked Questions

Should I buy or sell Accolade stock right now?

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Accolade in the last year. There are currently 4 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ACCD shares.
View ACCD analyst ratings
or view top-rated stocks.

What is Accolade's stock price target for 2024?

13 brokers have issued twelve-month price targets for Accolade's stock. Their ACCD share price targets range from $10.00 to $19.00. On average, they expect the company's share price to reach $15.14 in the next year. This suggests a possible upside of 65.7% from the stock's current price.
View analysts price targets for ACCD
or view top-rated stocks among Wall Street analysts.

How have ACCD shares performed in 2023?

Accolade's stock was trading at $7.79 at the start of the year. Since then, ACCD shares have increased by 17.3% and is now trading at $9.14.
View the best growth stocks for 2023 here
.

When is Accolade's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, January 8th 2024.
View our ACCD earnings forecast
.

How were Accolade's earnings last quarter?

Accolade, Inc. (NASDAQ:ACCD) announced its quarterly earnings results on Wednesday, October, 4th. The company reported ($0.43) EPS for the quarter, beating analysts' consensus estimates of ($0.54) by $0.11. The business earned $96.86 million during the quarter, compared to the consensus estimate of $94.09 million. Accolade had a negative trailing twelve-month return on equity of 30.58% and a negative net margin of 37.24%. The business's revenue for the quarter was up 10.5% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.66) earnings per share.

What guidance has Accolade issued on next quarter's earnings?

Accolade updated its third quarter 2024 earnings guidance on Wednesday, October, 4th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $95.00 million-$97.00 million, compared to the consensus revenue estimate of $96.57 million.

What is Rajeev Singh's approval rating as Accolade's CEO?

152 employees have rated Accolade Chief Executive Officer Rajeev Singh on Glassdoor.com. Rajeev Singh has an approval rating of 74% among the company's employees.

What other stocks do shareholders of Accolade own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Accolade investors own include CVS Health (CVS), Johnson & Johnson (JNJ), RTX (RTX), Alibaba Group (BABA), Home Depot (HD), Procter & Gamble (PG), Thermo Fisher Scientific (TMO), Cisco Systems (CSCO) and Intel (INTC).

When did Accolade IPO?

(ACCD) raised $176 million in an initial public offering (IPO) on Thursday, July 2nd 2020. The company issued 8,800,000 shares at a price of $19.00-$21.00 per share. Goldman Sachs, Morgan Stanley and BofA Securities acted as the underwriters for the IPO and Piper Sandler, Credit Suisse, William Blair, Baird and SVB Leerink were co-managers.

Who are Accolade's major shareholders?

Accolade's stock is owned by many different institutional and retail investors. Top institutional investors include JPMorgan Chase & Co. (8.63%), Brown Advisory Inc. (7.96%), ARK Investment Management LLC (7.93%), Rock Springs Capital Management LP (3.82%), Sumitomo Mitsui Trust Holdings Inc. (2.36%) and Northern Trust Corp (0.97%). Insiders that own company stock include Colin Mchugh, Michael W Hilton, Rajeev Singh, Richard Eskew, Robert N Cavanaugh, Stephen H Barnes and Thomas J Neff.
View institutional ownership trends
.

How do I buy shares of Accolade?

Shares of ACCD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ACCD) was last updated on 12/4/2023 by MarketBeat.com Staff

My Account -